One of 2024's best stocks is at an intriguing entry pointHims & Hers Health Inc (NYSE:HIMS) stock is sitting out the broad market rally today, last seen down 8.4% to trade at $26.15. The personalized healthcare company -- a key player in the weight loss drug craze -- is taking a hit after the Food and Drug Administration (FDA) announced Eli Lilly's (LLY) weight-loss drug shortage was resolved. HIMS is on track for its worst single-session decline since Nov. 14, when Amazon.com (AMZN) entered the telehealth ...